{"gao_id": "GAO-23-105270", "published": "2023-09-05T12:00:00Z", "released": "2023-09-05T08:00:00Z", "summary": "Medicare beneficiaries can have prescription drugs covered via private insurance plans participating in the Medicare Part D program. Premiums and drug costs vary by plan, as do plans' lists of covered drugs\u2014known as \"formularies.\" Drug makers may give plans rebates in exchange for preferred placement over competitors on formularies. The rebates may lower plan premiums, but they don't reduce beneficiaries' payments for the drugs. We...", "title": "Medicare Part D: CMS Should Monitor Effects of Rebates on Plan Formularies and Beneficiary Spending", "topics": ["Drug prices", "Pharmacy", "Federal spending", "Pharmacy benefit managers", "Generic drugs", "Medicare", "Beneficiaries", "Health Care", "Drugs", "Low-income subsidy", "Prescription drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-23-105270", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-23-105270-highlights.pdf"}, {"title": "Full Report (65 pages)", "url": "https://www.gao.gov/assets/gao-23-105270.pdf"}, {"title": "Accessible PDF (83 pages)", "url": "https://www.gao.gov/assets/830/828768.pdf"}]}